Develops THB001, a selective oral KIT inhibitor. Targets severe allergic diseases like chronic urticaria and asthma. Now — the numbers.
There is not enough trading history here to call this an established business.
Red columns mark years that ended in a loss.
If every debt were paid off today, $281.9M would still be left in the vault — a solid cushion for hard times.
The market pays 5.3× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Analysts' average target sits 200% above today's price.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 78% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $285.1M in the vault; even if every debt were paid off, $281.9M would remain.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.